Collectively, these findings suggest that the four biomarkers, namely, CHI3L1, FCGBP, VSIG2, and TFF2, hold the potential for diagnosing GC, particularly in cases of gastritis and early‐stage GC. This evidence concerns the gene TFF2 and gastric cancer.